$Vertex, Inc.(VERX)$ bullish Vertex is likely on the verge of realizing its strategic plan to diversify its portfolio of medicines.
If you're not familiar with Vertex, its claim to fame over the last decade has been its cystic fibrosis (CF) therapies. Sales of its four medicines for CF led to net income of more than $3.2 billion in 2022. Given that CF is a rare genetic pulmonary disease that only affects 88,000 people in the Western world, and that the company already treats all but around 25,000 of them, its mastery of the market is hard to overstate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- PorkyO·2023-04-14kLikeReport
- Tigaa·2023-04-13okkLikeReport
- Investforget·2023-04-13KLikeReport
- happymoney·2023-04-13OkLikeReport
- CGOO·2023-04-13Bullish goLikeReport
- Aeron2020·2023-04-13OkLikeReport
- Nick K·2023-04-13okLikeReport